Content by bit.bio

Induced pluripotent stem cell-derived microglia generated with precision cell reprogramming technology can create more reliable in vitro assays.

A new iPSC-derived cellular tool with built-in Cas9 expression enables high efficiency knockout screening for drug target identification and validation.

Researchers use a high throughput microelectrode array platform to test neural activity in an in vitro model of ALS.

Accelerating the production of induced pluripotent stem cell-derived models accelerates publishable neuroscience research.

bit.bio’s new ioGlutamatergic Neurons HTT^50CAG/WT provide a human, cell-based, in vitro model of Huntington’s Disease (HD) that accurately reflects the disease genotype. Offering industry-leading consistency and scalability, this first product from the new ioDisease Model portfolio has been developed to support key applications within drug discovery including target identification and high-throughput screening.